Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of unresectable sarcoma patients with chemotherapy failure. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rate (ORR) (CR+PR), disease control rate (DCR) (CR+PR+SD), and overall survival (OS). To observe the safety of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of sarcoma
Epistemonikos ID: c3740773663eaa2dc54bdfa428ce385606db0ed7
First added on: May 22, 2024